| http://www.w3.org/ns/prov#value | - and other bleeding disorders, immune deficiencies, vaccines and other products, rose 1% to $1.6 billion.Excluding the impact of currency exchange rates, sales would have been up 4% as demand rose, particularly in the U.S. for its ADVATE treatment for hemophilia.In Medical Products, sales also increased 1%, to $2 billion, on solid gains for the company's dialysis products, as well as certain injec
|
